Pay in 4 interest-free payments of $6.30 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Conditions Locations Treatment Type Trial Phase Trial Status Paid Participation Trial Details Key Eligibility Criteria 1205 Participants Needed Trial Details Key Eligibility Criteria 698 Participants Needed Trial Details Key Eligibility Criteria 4500 Participants Needed Trial Details Key Eligibility Criteria 228 Participants Needed Trial Details Key Eligibility Criteria 1200 Participants Needed Trial Details Key Eligibility Criteria 80 Participants Needed Trial Details Key Eligibility Criteria 70 Participants Needed Trial Details Key Eligibility Criteria 120 Participants Needed Trial Details Key Eligibility Criteria 360 Participants Needed Trial Details Key Eligibility Criteria 1759 Participants Needed Trial Details Key Eligibility Criteria 36 Participants Needed Trial Details Key Eligibility Criteria 32 Participants Needed Trial Details Key Eligibility Criteria 166 Participants Needed Trial Details Key Eligibility Criteria 2150 Participants Needed Trial Details Key Eligibility Criteria 700 Participants Needed Trial Details Key Eligibility Criteria 1650 Participants Needed Trial Details Key Eligibility Criteria 845 Participants Needed Trial Details Key Eligibility Criteria 357 Participants Needed Trial Details Key Eligibility Criteria 1000 Participants Needed Trial Details Key Eligibility Criteria 120 Participants Needed "My orthopedist recommended a half replacement of my right knee
Simultaneously, these medications suppress glucagon secretion from pancreatic alpha cells, further contributing to improved glycemic control
March 25, 2025
5, 6 Furthermore, non-clinical and clinical studies have demonstrated increased satiety, reduced food intake and subsequent reductions in body weight following administration of GLP-1, 7, 8 leading to investigations into its potential for the treatment of obesity
